C-Section bleeding study: does tranexamic acid help clotting?
NCT ID NCT03742947
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examined how the drug tranexamic acid (TXA) affects blood clotting in women having planned C-sections. Researchers measured clot breakdown times in 34 participants to see if TXA could help prevent heavy bleeding after delivery. The goal was to better understand how TXA works in this setting, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
34 people
The number who actually took part.
- Started
-
Jan 2019
- Finished
-
Jan 2020
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * patient randomized into TRAAP2 study (NCT03431805): * adult women admitted for a planned caesarean delivery, * at term ≥ 34 weeks, * haemoglobin level at the last blood sample \>9g/dl, * blood Formula numbering within 7 days before caesarean delivery, informed signed consent) * informed signed consent for BIO-TRAAP Exclusion Criteria: * patient not included into TRAAP2 study: * previous thrombotic event or pre-existing pro-thrombotic disease, * epileptic state or history of seizures, * presence of any chronic or active cardiovascular disease outside hypertension, * any chronic or active renal disease including renal, chronic or acute insufficiency (glomerular flow \<90mL / min), and chronic or active liver disease at risk thrombotic or haemorrhagic, * autoimmune disease, * sickle cell disease, * placenta praevia, * placenta accreta/increta/percreta, * abruption placentae, * eclampsia, * HELLP syndrome, * in utero fetal death, * administration of low-molecular-weight heparin or antiplatelet agents during the week before delivery, * general anaesthesia, * hypersensitivity to tranexamic acid or concentrated hydrochloric acid, instrumental extraction failure, * multiple pregnancy with genital delivery of the first twin and caesarean delivery for the second or at third trimester, * poor understanding of the French language
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hyperfibrinolysis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Bordeaux
Bordeaux, 33000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a slower oxytocin infusion prevent dangerous blood pressure drops in C-Sections?
- A 12-minute video could save new mothers' lives – can it teach them to spot danger?
- Can a simple calcium tablet help prevent postpartum bleeding?
- Medical glue vs. internal bleeding: a new hope?
- Which drug stops Post-Birth bleeding better? a Head-to-Head test
- Could a simple calcium injection prevent dangerous bleeding after childbirth?